Last reviewed · How we verify
NCT05750758
Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty
NA trial testing rivaroxaban in Acute Coronary Syndrome in 140 participants. Completed in 1 December 2023.
10 August 2023
Quick facts
| Lead sponsor | Henan Institute of Cardiovascular Epidemiology |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 140 |
| Start date | 20 February 2023 |
| Primary completion | 10 August 2023 |
| Estimated completion | 1 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- rivaroxaban (rivaroxaban) — full drug profile →
Conditions studied
- Acute Coronary Syndrome — all drugs for Acute Coronary Syndrome →
Sponsor
Henan Institute of Cardiovascular Epidemiology
Who can join
Adults 18 to 60, any sex, with Acute Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The target population of this interventional study was ACS patients with drug-coated balloons. The main discussion : 1.1 months of rivaroxaban combined with dual antiplatelet therapy compared with dual antiplatelet therapy alone, late lumen loss at 6 months. 2. To determine the safety of the regimen with bleeding events as the end point. Subjects were randomly assigned to two groups, one receiving routine DAPT for six months and one receiving DAPT plus one month of rivaroxaban 2.5 mg bid
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Rivaroxaban for patients with coronary dissection after drug-coated balloon angioplasty : A Randomized Controlled Trial
Liu K, Guo Q, Qingbo S, Nie M, et al · · 2024 · DOI 10.1101/2024.01.04.24300877
Verify or expand the search:
- PubMed search for NCT05750758
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of rivaroxaban
Trials testing the same drug.
- NCT06689241 — Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery · NA · recruiting
- NCT05838664 — A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) · completed
- NCT04808934 — NOAC Portuguese Real World Study · withdrawn
- NCT04006288 — Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary · Phase 4 · completed
- NCT03441633 — Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf) · completed
Other recruiting trials for Acute Coronary Syndrome
Currently open trials in the same condition.
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
- NCT07032389 — A Polypill for Acute Coronary Syndrome · Phase 2 · recruiting
- NCT07102628 — Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronar · Phase 3 · recruiting
- NCT06416813 — Preventive Intervention Value of DCB in Vulnerable Coronary Atherosclerotic Plaques · NA · active not recruiting
Other Henan Institute of Cardiovascular Epidemiology trials
Trials by the same sponsor.
- NCT07514624 — CRIC Combined With MFT for MFR in Patients With Incomplete Revascularization of CAD · NA · not yet recruiting
- NCT06820970 — CRIC Combined With MFT for Cardiovascular Adverse Events in Patients With Incomplete Revascularization of CAD · NA · recruiting
- NCT06769256 — Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden · Phase 4 · recruiting
- NCT07181356 — Effects of Long-term Remote Ischemic Preconditioning on Clinical Outcome in Patients With Acute Myocardial Infarction · NA · recruiting
- NCT04308551 — Effect of Indobufen and Aspirin on Platelet Aggregation and Long Term Prognosis in Patients With Coronary Heart Disease · NA · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05750758 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Henan Institute of Cardiovascular Epidemiology
- Last refreshed: 23 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05750758.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing